
CO.26
NCT02870920
CO26
Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies
Status:
Closed to Accrual

II
Phase

Palliative
Line of Therapy

Advanced / Metastatic
Disease Stage

Biomarker(s)
N/A
Investigational
Product
Durvalumab +Tremelimumab
Treatment Arms
o Experimental: Durvalumab plus Tremelimumab and Best Supportive Care
o Active Comparator: Best Supportive Care